Myriad RBM, Inc. is the world’s leading multiplexed immunoassay testing laboratory that solves complex drug development challenges with innovative biomarker services and a novel whole blood immunophenotyping device (TruCulture®). Myriad RBM’s internally developed and manufactured immunoassay kits based on Multi-Analyte Profiling (MAP) and ultrasensitive Single-Molecule Array (SimoaTM) technology provides translational and clinical researchers with reproducible and quantitative data for a few or hundreds of human proteins. The comprehensive menu provides extensive coverage of numerous pathways, and delivers accurate pharmacodynamic and safety assessments. Myriad RBM’s CLIA certified biomarker testing laboratory is located in Austin, TX. Myriad RBM is a wholly owned subsidiary of Myriad Genetics, Inc. (MYGN), a leading molecular diagnostic company based in Salt Lake City, Utah which develops and markets novel predictive medicine, personalized medicine and prognostic medicine tests.
Live Webinar taking place
Thursday 29th October 2020, 15:00 - 16:00 GMT
Register for the webinar that includes three short presentations on Spatial Biology and one narrated poster. The illustrious presenters will share interesting insights on how to uncover biomarkers in situ and how to deconvolute scRNA data and spatial profiling results in situ.